{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:38:20Z","timestamp":1759333100121,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:00:00Z","timestamp":1648857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:00:00Z","timestamp":1648857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10072-022-05922-2","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T01:10:41Z","timestamp":1648861841000},"page":"4081-4083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-585X","authenticated-orcid":false,"given":"Masahiro","family":"Mimori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Maku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Mitsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,2]]},"reference":[{"key":"5922_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/s1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"5922_CR2","doi-asserted-by":"publisher","unstructured":"Cabal-Herrera AM, Mateen FJ (2021) COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica. J Neurol 268:4479\u20134482. https:\/\/doi.org\/10.1007\/s00415-021-10578-7","DOI":"10.1007\/s00415-021-10578-7"},{"key":"5922_CR3","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","volume":"268","author":"UH Oy","year":"2021","unstructured":"Oy UH, Stankovic S, Kelbel C et al (2021) Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol 268:3125\u20133128. https:\/\/doi.org\/10.1007\/s00415-021-10428-6","journal-title":"J Neurol"},{"key":"5922_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/nejmoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder. New Engl J Med 381:614\u2013625. https:\/\/doi.org\/10.1056\/nejmoa1900866","journal-title":"New Engl J Med"},{"key":"5922_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis. Drugs 78:367\u2013376. https:\/\/doi.org\/10.1007\/s40265-018-0875-9","journal-title":"Drugs"},{"key":"5922_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jiph.2020.07.001","volume":"13","author":"MA Chowdhury","year":"2020","unstructured":"Chowdhury MA, Hossain N, Kashem MA et al (2020) Immune response in COVID-19: a review. J Infect Public Heal 13:1619\u20131629. https:\/\/doi.org\/10.1016\/j.jiph.2020.07.001","journal-title":"J Infect Public Heal"},{"key":"5922_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF et al (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256\u20131264. https:\/\/doi.org\/10.1038\/nbt1344","journal-title":"Nat Biotechnol"},{"key":"5922_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100590","volume":"28","author":"D Annane","year":"2020","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L et al (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. Eclinicalmedicine 28:100590. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100590","journal-title":"Eclinicalmedicine"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-05922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-05922-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-05922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T04:08:37Z","timestamp":1655784517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-05922-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,2]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["5922"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-05922-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,4,2]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}